Brand Name(s):Femara

Indication:Oestrogen-receptor positive breast cancer in post-menopausal women



Review Date:Jan-25

NICE Dec 19 – SPC updated with warnings about the risk of tendonitis and tendon rupture, as per PRAC recommendation
LINK; https://www.evidence.nhs.uk/document?id=2197947&returnUrl=search%3fq%3dletrozole&q=letrozole

For patients under the care of DBTH FT, the specialist service will request a DEXA scan when aromatase inhibitors are started, and then write to the GP with the result and recommendation. Whilst the patient is still under DBTH FT followup (for 5 years post treatment) the service will arrange follow up DEXA scans and write to the GP with the result. This is managed by the Nurse Practitioner.
When patients are discharged, DBTH FT will write to the GP. If aromatase inhibtors are to be continued the service writes to the GP, asking the GP to take over care and informing the GP when the next DEXA scan is due. A date is also provided when the aromatase inhibitor is due to be stopped.
Written communication from Miss C.Rogers, Clinical Lead for Breast Surgery, DBTH FT
October 2018
NICE CG164 can be found at:http://www.nice.org.uk/nicemedia/live/14188/64202/64202.pdf
Issued: June 2013